Evidence map›Paper›PMID 37014438›Full record

ArticleMetabolomics : Official journal of the Metabolomic Society2023

Circulating metabolites as potential biomarkers for the early detection and prognosis surveillance of gastrointestinal cancers.

Guodong Song, Li Wang, Junlong Tang, Haohui Li, Shuyu Pang, Yan Li, Li Liu, Junyuan Hu

Open access · hybridAbstract read
In one paragraph

Article in Metabolomics : Official journal of the Metabolomic Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Guodong Song *The Second Hospital of Tianjin Medical University, No 23. Pingjiang Road, Hexi District, 300211, Tianjin, China.
Li Wang *The Second Hospital of Tianjin Medical University, No 23. Pingjiang Road, Hexi District, 300211, Tianjin, China.
Junlong TangMetanotitia Inc, No 59. Gaoxin South 9Th Road, Yuehai Street, Nanshan District, Shenzhen, 518056, Guangdong, China.
Haohui LiMetanotitia Inc, No 59. Gaoxin South 9Th Road, Yuehai Street, Nanshan District, Shenzhen, 518056, Guangdong, China.
Shuyu PangMetanotitia Inc, No 59. Gaoxin South 9Th Road, Yuehai Street, Nanshan District, Shenzhen, 518056, Guangdong, China.
Yan LiMetanotitia Inc, No 59. Gaoxin South 9Th Road, Yuehai Street, Nanshan District, Shenzhen, 518056, Guangdong, China.
Li LiuMetanotitia Inc, No 59. Gaoxin South 9Th Road, Yuehai Street, Nanshan District, Shenzhen, 518056, Guangdong, China. li.liu@metanotitia.com.
Junyuan HuMetanotitia Inc, No 59. Gaoxin South 9Th Road, Yuehai Street, Nanshan District, Shenzhen, 518056, Guangdong, China. junyuan.hu@metanotitia.com.
Shenzhen Metro (China) · CNTianjin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsTwo of the most lethal gastrointestinal (GI) cancers, gastric cancer (GC) and colon cancer (CC), are ranked in the top five cancers that cause deaths worldwide. Most GI cancer deaths can be reduced by earlier detection and more appropriate medical treatment. Unlike the current "gold standard" techniques, non-invasive and highly sensitive screening tests are required for GI cancer diagnosis. Here, we explored the potential of metabolomics for GI cancer detection and the classification of tissue-of-origin, and even the prognosis management.

methodsPlasma samples from 37 gastric cancer (GC), 17 colon cancer (CC), and 27 non-cancer (NC) patients were prepared for metabolomics and lipidomics analysis by three MS-based platforms. Univariate, multivariate, and clustering analyses were used for selecting significant metabolic features. ROC curve analysis was based on a series of different binary classifications as well as the true-positive rate (sensitivity) and the false-positive rate (1-specificity).

resultsGI cancers exhibited obvious metabolic perturbation compared with benign diseases. The differentiated metabolites of gastric cancer (GC) and colon cancer (CC) were targeted to same pathways but with different degrees of cellular metabolism reprogramming. The cancer-specific metabolites distinguished the malignant and benign, and classified the cancer types. We also applied this test to before- and after-surgery samples, wherein surgical resection significantly altered the blood-metabolic patterns. There were 15 metabolites significantly altered in GC and CC patients who underwent surgical treatment, and partly returned to normal conditions.

conclusionBlood-based metabolomics analysis is an efficient strategy for GI cancer screening, especially for malignant and benign diagnoses. The cancer-specific metabolic patterns process the potential for classifying tissue-of-origin in multi-cancer screening. Besides, the circulating metabolites for prognosis management of GI cancer is a promising area of research.

Indexed as

Colonic NeoplasmsGastrointestinal NeoplasmsStomach NeoplasmsBiomarkers, TumorHumansMetabolomicsPrognosisBiomarkers, TumorBiomarkerCirculating metabolitesColon cancerEarly detectionGastric cancerMetabolomicsSurveillance

Identifiers

PMID37014438
PMCPMC10073066
OpenAlexW4362523860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.